LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Home・Akciju saraksts・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Slēgts

9.4 -2.08

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.32

Max

9.51

Galvenie mērījumi
By Trading Economics
Ienākumi	4.2M -23M
Peļņas marža	-2,027.003
Darbinieki	83
EBITDA	6.6M -23M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+42.25% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	91M 678M
Iepriekšējā atvēršanas cena	11.48
Iepriekšējā slēgšanas cena	9.4

Ventyx Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 21. nov. 22:42 UTC

Tirgus saruna

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

2025. g. 21. nov. 21:50 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 21. nov. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 21. nov. 21:47 UTC

Tirgus saruna

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

2025. g. 21. nov. 21:43 UTC

Tirgus saruna

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

2025. g. 21. nov. 20:18 UTC

Tirgus saruna

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

2025. g. 21. nov. 20:14 UTC

Tirgus saruna

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

2025. g. 21. nov. 19:48 UTC

Tirgus saruna

Precious Metals Fall for the Week -- Market Talk

2025. g. 21. nov. 19:44 UTC

Peļņas

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

2025. g. 21. nov. 19:37 UTC

Tirgus saruna

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

2025. g. 21. nov. 19:27 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2025. g. 21. nov. 19:27 UTC

Tirgus saruna

Peļņas

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

2025. g. 21. nov. 19:20 UTC

Tirgus saruna

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

2025. g. 21. nov. 18:44 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

2025. g. 21. nov. 18:37 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

2025. g. 21. nov. 18:34 UTC

Tirgus saruna

Peļņas

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

2025. g. 21. nov. 18:28 UTC

Peļņas

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

2025. g. 21. nov. 18:03 UTC

Tirgus saruna

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

2025. g. 21. nov. 17:24 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 21. nov. 17:24 UTC

Tirgus saruna

Intuit Seen on Path to Increase Growth -- Market Talk

2025. g. 21. nov. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 21. nov. 17:05 UTC

Tirgus saruna

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

2025. g. 21. nov. 16:56 UTC

Tirgus saruna

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

2025. g. 21. nov. 16:47 UTC

Tirgus saruna

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

2025. g. 21. nov. 16:35 UTC

Iegādes, apvienošanās, pārņemšana

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

2025. g. 21. nov. 16:09 UTC

Peļņas

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

2025. g. 21. nov. 15:59 UTC

Tirgus saruna

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

2025. g. 21. nov. 15:59 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 21. nov. 15:23 UTC

Tirgus saruna

Bank of Canada Not Expected to Be Swayed by Canadian Retail Trade Data -- Market Talk

2025. g. 21. nov. 15:17 UTC

Tirgus saruna

Canadian Consumer Spending Softening, But Could Be Worse -- Market Talk

Salīdzinājums

Cenas izmaiņa

Ventyx Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

42.25% augšup

Prognoze 12 mēnešiem

Vidējais 13.67 USD 42.25%

Augstākais 21 USD

Zemākais 2 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ventyx Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ventyx Biosciences Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.